GlassScriptPhysician profile
Daniel L Wagner
NPI 1942419452
$2,087.22
in general payments reported to CMS, 2019-2025
21 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $38.76 · 2023: $389 · 2024: $1,077 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $273.80 | 2023-2025 | |
| Cvrx, INC. | $250.14 | 2024-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $183.27 | 2023-2025 | |
| Esperion Therapeutics, INC. | $151.94 | 2023-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $148.38 | 2023-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $138.64 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $128.84 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $127.34 | 2023-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $111.06 | 2023-2025 | Watchman Access System |
| Amgen INC. | $108.39 | 2022-2025 | Repatha, Repatha |
| Siemens Medical Solutions USA, INC. | $99.72 | 2024-2025 | Acuson Origin Diagnostic Ultrasound System |
| Abiomed | $54.51 | 2024-2025 | Impella |
| Merck Sharp & Dohme LLC | $50.25 | 2024-2025 | Verquvo |
| Medtronic, INC. | $50.19 | 2023-2024 | Linq II |
| Lantheus Medical Imaging, INC. | $47.05 | 2023 | Definity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $42.07 | 2024 | |
| Inspire Medical Systems, INC. | $34.37 | 2024 | Inspire |
| Chiesi USA, INC. | $30.31 | 2023-2024 | Kengreal, Cleviprex |
| Heartflow, INC. | $26.95 | 2024 | |
| Coopersurgical, INC. | $15.47 | 2025 | Paragard T 380a |
| Exeltis, USA INC. | $14.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.